Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 3
Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
This discussion explores the occurrence and risk factors of neutropenia associated with SG treatment, comparing clinical practice experiences with trial data.
Video Player is loading.
Video content above is prompted by the following:
- Let’s dive deeper into some of the specific adverse events that we may see with SG in our clinical practice….
- How often do you see neutropenia in your clinical practice? How does it compare to the rates reported in clinical trials (ASCENT, TROPiCS-02)?
- Are there risk factors that can help predict those who are at higher risk for developing neutropenia?
Related Content:
